{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:12:54Z","timestamp":1772842374907,"version":"3.50.1"},"reference-count":15,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"unspecified","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2026,1,31]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The recent rollout of nirsevimab across multiple countries represents an important advancement in respiratory syncytial virus (RSV) prevention. However, real-world evidence on how its effectiveness varies with infant age and time since administration, and on the characteristics of breakthrough infections, remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>In this study, we aimed to conduct an international collaborative study to assess the real-world effectiveness of nirsevimab by monthly interval of chronological age and time since administration and to understand the characteristics of breakthrough infections. Both individual-participant-level data (IPD) and aggregated data will be collected from international collaborators identified by systematic review, existing collaborative network and academic conferences. The effectiveness of nirsevimab will be assessed by a test-negative study design, and a two-stage IPD meta-analysis will be conducted for data synthesis; a one-stage IPD meta-analysis will also be conducted among a subset of IPD data with sufficient sample size as an exploratory analysis. We will also describe the epidemiological, clinical and molecular features of breakthrough infections and compare them with infants and young children who were either unvaccinated and infected or vaccinated but not infected. The study will provide detailed insights into the dynamic effectiveness of nirsevimab and the characteristics of breakthrough cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study protocol has been approved by the Ethics Committee of Nanjing Medical University (2025\u2013179). Ethical approval for the contributing studies is expected to be obtained independently by local investigators from their respective ethics committees. Findings will be presented at international conferences and submitted to peer-reviewed journals for publication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2025-003850","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:35:12Z","timestamp":1772807712000},"page":"e003850","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Understanding real-world effectiveness of nirsevimab and the characteristics of breakthrough RSV infections: a study protocol of individual-participant-level data meta-analysis (the GEMINI study)"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5541-5815","authenticated-orcid":false,"given":"Shaolong","family":"Ren","sequence":"first","affiliation":[{"name":"Department of Epidemiology, National Vaccine Innovation Platform, School of Public Health, Nanjing Medical University, Nanjing, China"},{"name":"Key Laboratory of Public Health Safety and Emergency Prevention and Control Technology of Higher Education Institutions in Jiangsu Province, Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, National Vaccine Innovation Platform, School of Public Health, Nanjing Medical University, Nanjing, China"},{"name":"Key Laboratory of Public Health Safety and Emergency Prevention and Control Technology of Higher Education Institutions in Jiangsu Province, Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyu","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, National Vaccine Innovation Platform, School of Public Health, Nanjing Medical University, Nanjing, China"},{"name":"Key Laboratory of Public Health Safety and Emergency Prevention and Control Technology of Higher Education Institutions in Jiangsu Province, Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harish","family":"Nair","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, National Vaccine Innovation Platform, School of Public Health, Nanjing Medical University, Nanjing, China"},{"name":"Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8506-8439","authenticated-orcid":false,"given":"You","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, National Vaccine Innovation Platform, School of Public Health, Nanjing Medical University, Nanjing, China"},{"name":"Key Laboratory of Public Health Safety and Emergency Prevention and Control Technology of Higher Education Institutions in Jiangsu Province, Nanjing Medical University, Nanjing, China"},{"name":"Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK"},{"name":"Changzhou Third People\u2019s Hospital, Changzhou Medical Centre, Nanjing Medical University, Changzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"2026030606350716000_13.1.e003850.1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)00478-0"},{"key":"2026030606350716000_13.1.e003850.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110275"},{"key":"2026030606350716000_13.1.e003850.3","unstructured":"Beyfortus EMA . European Medicines Agency, 2022. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/beyfortus [Accessed 27 Nov 2022]."},{"key":"2026030606350716000_13.1.e003850.4","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103281","article-title":"Real-world uptake of nirsevimab, RSV maternal vaccine, and RSV vaccines for older adults: a systematic review and meta-analysis","volume":"84","author":"Trusinska","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2026030606350716000_13.1.e003850.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00215-9"},{"key":"2026030606350716000_13.1.e003850.6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2352-4642(25)00093-8","article-title":"Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis","volume":"9","author":"Sumsuzzman","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"key":"2026030606350716000_13.1.e003850.7","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2024.101007","article-title":"Effectiveness of nirsevimab against RSV-bronchiolitis in paediatric ambulatory care: a test-negative case-control study","volume":"44","author":"Lassoued","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2026030606350716000_13.1.e003850.8","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7309a4"},{"key":"2026030606350716000_13.1.e003850.9","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S1473-3099(25)00233-6","article-title":"Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): a retrospective observational study","volume":"25","author":"Torres","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026030606350716000_13.1.e003850.10","doi-asserted-by":"crossref","unstructured":"Chauvel C , Horvat C , Javouhey E , et al . Changes in respiratory syncytial virus-associated hospitalisations epidemiology after nirsevimab introduction in lyon, france. Preprints [Preprint] 2024. doi:10.22541\/au.172453041.15292517\/v1","DOI":"10.22541\/au.172453041.15292517\/v1"},{"key":"2026030606350716000_13.1.e003850.11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(24)00570-X","article-title":"Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study","volume":"25","author":"Fourati","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026030606350716000_13.1.e003850.12","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz683"},{"key":"2026030606350716000_13.1.e003850.13","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0140-6736(24)00138-7","article-title":"Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data","volume":"403","author":"Wang","year":"2024","journal-title":"The Lancet"},{"key":"2026030606350716000_13.1.e003850.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61400-1"},{"key":"2026030606350716000_13.1.e003850.15","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/s41467-025-56776-z","article-title":"Characterising the asynchronous resurgence of common respiratory viruses following the COVID-19 pandemic","volume":"16","author":"Zhao","year":"2025","journal-title":"Nat Commun"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2025-003850","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:35:13Z","timestamp":1772807713000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2025-003850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,6]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/bmjresp-2025-003850"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2025-003850","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}